DEINOVE AND ESPCI PARIS OBTAIN FUNDING FROM THE ANR.

 
FREE EXCERPT

DEINOVE has obtained, jointly with ESPCI Paris, a 300k grant from the ANR for the co-development of an innovative system for the isolation, culture and screening of bacteria.

The Deinodrop partnership research project, involving DEINOVE and ESPCI Paris, was selected by the ANR as part of the call for collaborative research projects in the field of Healthcare technologies. This two-year project has been granted 300k in funding.

This project, which will support the AGIR program, aims to develop an innovative microfluidic sorting system, into drops containing environmental bacteria, in which each drop constitutes a microreactor. Once developed, this technology will offer many benefits to accelerate research and increase the success rate of the AGIR program:

- Increased screening sensitivity, for better detection of antibiotics of interest;

- Increased bacterial screening and sorting rate, up to 800 drops per second, while optimizing the amount of reagents used;

- Ability to detect, sort and analyze bacteria said to be non- cultivable under conventional laboratory conditions.

"We are proud that the DEINODROP project has been selected by the ANR. Only 15% of the projects submitted are selected, obtaning this funding rewards the quality of our technology " says Raphael CALBRIX, Head of the DEINOVE Banking and Robotics platform. "Our objective is to develop a breakthrough technology in bacterial culture and selection in order to be able to analyze considerable quantities of microorganisms and discover new antibiotic activities that could address the major challenge of antibiotic resistance.

About The AGIR Program

The AGIR program Antibiotics Against Resistant Infectious Germs was selected in 2017 by the Investments for the Future Program and receives from Bpifrance a financial support of 14.6m over 5 years.

The AGIR program aims to explore a wide-ranging biodiversity, mainly rare micro-organisms in order to identify and develop a portfolio of drug candidates.

While the world lacks new antibiotics, research is still predominantly focused on a small number of micro-organisms of interest or on the construction by chemical synthesis of molecules derived from existing drugs.

Conversely, the AGIR program is developing new methods of collection, culture, evaluation of the antibiotic potential of rare bacterial strains, and optimization of the molecules of interest.

The AGIR program is run with the Charles Viollette Institute which brings its expertise in...

To continue reading

FREE SIGN UP